Clinical Trial Update: Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma [Phase 3]

View source ↗

Summary

Phase III study comparing tumor-infiltrating lymphocytes (TIL) therapy to ipilimumab in metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Tumor-infiltrating lymphocytes (TIL) therapy
• ipilimumab (ipilimumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Metastatic Melanoma | Phase 3 | Status: COMPLETED